[1]惠金子,赵德善.Tg、TgAb及TSH在分化型甲状腺癌术前的预测分析[J].国际放射医学核医学杂志,2015,39(2):110-115.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
　Hui Jinzi,Zhao Deshan.The prediction of risk of differentiated thyroid carcinoma with preoperative serum thyroid stimulating hormone, thyrogiobulin and antithyroglobulin antibody[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):110-115.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
点击复制

Tg、TgAb及TSH在分化型甲状腺癌术前的预测分析(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
39
期数:
2015年第2期
页码:
110-115
栏目:
出版日期:
2015-03-25

文章信息/Info

Title:
The prediction of risk of differentiated thyroid carcinoma with preoperative serum thyroid stimulating hormone, thyrogiobulin and antithyroglobulin antibody
作者:
惠金子;  赵德善
山西医科大学第二医院核医学科, 太原, 030001
Author(s):
Hui Jinzi;  Zhao Deshan
epartment of Nuclear Medicine, the Second Hospital of Shanxi Medical University, Taiyuan 030001, China
关键词:
甲状腺肿瘤; 甲状腺结节; 甲状腺球蛋白; 促甲状腺素; 抗甲状腺球蛋白抗体; 化学发光测定法; 放射免疫测定
Keywords:
Thyroid neoplasms; Thyroid nodule; Thyroglobulin; Thyrotropin; Antithyroglobulin antibody; Chemiluminescent measurements; Radioimmunoassay
DOI:
10.3760/cma.j.issn.1673-4114.2015.02.002
摘要:
目的 探讨患者术前血清促甲状腺激素、甲状腺球蛋白(Tg)、抗甲状腺球蛋白抗体(TgAb)浓度在预测甲状腺癌中的价值。方法 对122例接受手术治疗的甲状腺结节患者进行术前研究,以术后病理结果作为甲状腺结节性质的诊断金标准进行对照,其中分化型甲状腺癌55例,良性结节67例。采用化学发光法测定Tg和TSH;放射免疫分析法测定TgAb;采用彩色多普勒超声诊断仪检查甲状腺组织和颈部淋巴结。结果 甲状腺癌组的术前血清Tg水平(24.09±64.59) ng/ml和甲状腺良性结节组(23.37±112.14) ng/ml间的差异无统计学意义(Z=-1.092,P>0.05);甲状腺癌组的TSH水平(2.32±2.28) mIU/L高于甲状腺良性结节组(1.75±1.22) mIU/L,(Z=-2.107,P<0.05);甲状腺癌组Tg联合TgAb的阳性率(72.7%)高于甲状腺良性结节组(55.2%)(χ2=3.975,P<0.05).各指标预测甲状腺癌的受试者工作特征曲线示,TSH值的曲线下面积(AUC)为0.611[95%可信区间(95% CI):0.509~0.713],P<0.05,最佳临界值2.31 mIU/L,灵敏度和特异度分别为71.6%和50.9%;TSH:Tg值的AUC为0.617(95% CI:0.518~0.716),P<0.05,最佳临界TSH:Tg值为0.11 IU/mg,灵敏度和特异度分别为61.2%和50.9%;Tg曲线AUC<0.5.结论 术前血清Tg的异常升高不是甲状腺癌的独立预测因素,但其结合TgAb阳性、TSH:Tg值>0.11 IU/mg可作为甲状腺癌的危险预测因素,可能是甲状腺超声检查的一种有效补充诊断手段。
Abstract:
Objective To explore the values of preoperative serum thyroid stimulating hormone, thyroglobulin and antithyroglobulin antibody in predicting the risk of differentiated thyroid carcinoma. Methods 122 patients with thyroid nodules who got operations were studied, among which 55 patients with differentiated thyroid carcinoma(54 papillary and 1 follicular), 67 cases with benign thyroid nodules(40 nodular goiter and 27 adenoma).Serum thyroid-stimulating hormone(TSH) and thyroglobulin(Tg) were measured by chemiluminescence method.and antithyroglobulin antibody(TgAb) by radioimmunoas-say.Thyroid tissues and cervical lymph nodes were checked using color doppler ultrasonic diagnostic in-strument and the postoperative pathological results was regard as the gold standard of diagnosing thyroid cancer.Results Preoperative serum Tg levels in thyroid cancer group(24.09±64.59) ng/ml and benign thyroid nodules group(23.37±112.14) ng/ml had no statistical differences(Z=1.092, P>0.05).TSH levels in thyroid carcinoma group(2.32±2.28)mlU/L were higher than that in benign thyroid nodules group(1.75±1.22)mlU/L(Z=2.107, P<0.05).The positive rate ofTg combined with TgAb in thyroid cancer group(72.7%)was higher than that in benign thyroid nodules group(55.2%)(χ2=3.975, P<0.05).Receiver operating characteristic(ROC)curves showing sensitivity as a function of specificity were calculated for TSH, Tg levels and TSH:Tg values to evaluate the potential accuracy of the three index as predicting dif-ferentiated thyroid carcinoma.The area under the curve(AUC)of TSH was 0.6 1 1 195% confidence interval(95%CI):0.509-0.713], P<0.05.The optimum threshold in ROC curves of TSH was 2.31 mlU/L.The sensitivity and specificity of TSH were 71.6% and 50.9% respectively.The AUC of TSH:Tg values was 0.617(95%CI:0.518-0.716), P<0.05.The best critical value of TSH:Tgwas 0.11 IU/mg.The sensitiv-ity and specificity of TSH:Tg were 61.2% and 50.9% respectively.The AUC of Tg was less than 0.5. Conclusions Serum thyroglobulin elevated abnormally is not an independent predicting factor of differen-tiated thyroid cancer.The elevated Tg levels and/or positive TgAb and TSH:Tg>0.1 1 IU/mg can be used as effective supplementary means of ultrasound examination in predicting differentiated thyroid carcinoma.

参考文献/References:

[1] Cooper DS,Doberly GM,Haugen BR,et al.Revised American thy-roid association management guidelines for patients with thyroid cancer:the American thyroid association(ATA) guidelines task-force on thyroid nodules and differentiated thyroid cancer[J].Thy-roid, 2009,19(11):1167-1214.
[2] Gharib H,Papini E,Paschke R,et al.American association of clini-cal endocrinologists,associazione medici endocrinologi,and Euro-pean thyroid association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules:executive sum-mary ofrecommendations[J].Endocr Pract,2010,16(3):468-475.
[3] Hegedüs L.Thyroid ultrasound[J].Endocrinol Metab Clin North Am,2001,30(2):339-360,viii-ix.
[4] Schlumberger MJ,Torlantano M,Papillary and follicular thyroid carcinoma[J].Best Pract Res Clin Endocrinol Metab,2000,14(4): 60l-613.
[5] Jung KW,Park S,Kong HJ,et al.Cancer statistics in Korea:inci-dence,mortality and survival in 2006-2007[J].J Korean Med Sei, 2010,25(8):1113-1121.
[6] Crowther A,Giles K,Archer L.Thyroid FNAC inadequacy rates[J]. Clin Radiol,2014,69 Suppl 1:S12.
[7] Nascimento C,Borget I,Troalen F,et al.Uhrasensitive serum thy-roglobulin measurement is useful for the follow-up of patients treated with total thyroidectomy without radioactive Iodine ablation[J].Eur J Endocrinol,2013,169(5):689-693.
[8] Hrafnkelsson J,Tulinius H,Kjeld M,et al.Serum thyroglobulin as a risk factor for thyroid carcinoma[J].Acta Oncol(Madr),2000,39(8):973-977.
[9] Lee EK,Chung KW,Min HS,et al.Preoperative serum thyroglobu-lin as a useful predictive marker to differentiate follicular thyroid cancer from benign nodules in indeterminate nodules[J].J Korean Med Sci,2012,27(9):1014-1018.
[10] Rinaldi S,Plummer M,Biessy C,et al.Thyroid-stimulating hor-mone,thyroglobulin,and thyroid hormones and risk of differentiat-ed thyroid carcinoma:the EPIC study[J/OL].J Natl Cancer Inst, 2014,106(6):dju097[2014-11-30].http://jnci.oxfordjournals.org/content/106/6/dju097.full.pdf+html.
[11] Haymart MR,Glinberg SL,Liu J,et al.Higher serum TSH in thy-roid cancer patients occurs Independent of age and correlates with extrathyroidal extension[J].Clin Endocrinol(Oxf),2009,71(3): 434-439.
[12] 官青,张凌,魏文俊,等.术前血清TSH与TGAB对于分化型甲状腺癌的预测价值[C]//2011国际暨全国第十一届头颈肿瘤学术大会论文汇编.杭州:中国抗癌协会头颈肿瘤专业委员会, 2011:361-362.
[13] 王丽娜,杨中元,李浩,等.术前血清促甲状腺素与甲状腺球蛋白的比值是甲状腺结节的有效诊断方法[C]//2014第六届全国甲状腺肿瘤学术大会论文集.天津:中国抗癌协会甲状腺癌专业委员会,2014:320-320.

相似文献/References:

[1]李盼丽,宋少莉.碘难治性分化型甲状腺癌靶向药物治疗进展[J].国际放射医学核医学杂志,2016,40(3):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
　Li Panli,Song Shaoli.Radioactive iodine refractory differentiated thyroid cancer targeted therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
[2]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
　yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[3]陈立,陈跃.分化型甲状腺癌骨转移诊断及疗效评价的核素显像研究进展[J].国际放射医学核医学杂志,2016,40(6):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
　Chen Li,Chen Yue.Diagnosis and evaluation of curative effect progress of radionuclide imaging methods in differentiated thyroid cancer of bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
[4]刘斌,潘明志.BRAF基因突变对甲状腺乳头状癌诊治价值的研究进展[J].国际放射医学核医学杂志,2015,39(2):154.[doi:10.3760/cma.j.issn.1673-4114.2015.02.011]
　Liu Bin,Pan Mingzhi.Advances in value of BRAF gene mutation on the diagnosis and treatment of papillary thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):154.[doi:10.3760/cma.j.issn.1673-4114.2015.02.011]
[5]胡斌,王锦锋,毛秋粉.18F-FDG PET/CT显像在Tg阳性131I全身显像阴性的分化型甲状腺癌患者中的应用价值[J].国际放射医学核医学杂志,2015,39(3):242.[doi:10.3760/cma.j.issn.1673-4114.2015.03.012]
　Hu Bin,Wang Jinfeng,Mao Qiufen.The application value of 18F-FDG PET/CT in patients with differentiated thyroid cancer of high thyroglobulin level and negative 131I whole body scan[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):242.[doi:10.3760/cma.j.issn.1673-4114.2015.03.012]
[6]刘鹏杰,唐铭,邓智勇,等.131I治疗儿童分化型甲状腺癌期间出现低钙血症伴癫痫发作一例[J].国际放射医学核医学杂志,2015,39(4):352.[doi:10.3760/cma.j.issn.1673-4114.2015.04.017]
[7]寇莹,刘建中,郝新忠,等.甲状腺癌131I治疗后全身扫描盆腔浓聚131I的临床分析[J].国际放射医学核医学杂志,2014,38(1):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
　Kou Ying,Liu Jianzhong,Hao Xinzhong,et al.Analysis of pelvic 131I uptake after 131I whole body scan in patients with thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
[8]李敬彦,蒋宁一.分化型甲状腺癌术后131I清甲治疗方法的相关问题[J].国际放射医学核医学杂志,2014,38(1):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
　Li Jingyan,Jiang Ningyi.Issues related to radioactive iodine ablation in patients with differentiated thyroid carcinoma under-going thyroid surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
[9]马春旭,袁卫红.甲状腺结节影像学诊断研究进展[J].国际放射医学核医学杂志,2014,38(1):48.[doi:10.3760/cma.j.issn 1673-4114.2014.01.010]
　Ma Chunxu,Yuan Weihong.Advanced research on imaging diagnosis of thyroid nodule[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):48.[doi:10.3760/cma.j.issn 1673-4114.2014.01.010]
[10]成钊汀,谭建.分化型甲状腺癌术后患者131I治疗的辐射剂量与防护[J].国际放射医学核医学杂志,2014,38(2):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]
　Cheng Zhaoting,Tan Jian.Radiation dose and protection of differentiated thyroid carcinoma postoperative patients with 131I treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]
[11]龙再颖,曲新艳,单英丽.99Tcm-MIBI显像对甲状腺结节良恶性鉴别诊断价值的研究[J].国际放射医学核医学杂志,2010,34(2):80.[doi:10.3760/cma.j.issn.1673-4114.2010.02.004]
　LONG Zai-ying,QU Xin-yan,SHAN Ying-li.The diagnostic value of 99Tcm-MIBI imaging to benign and malignant thyroid lesions[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(2):80.[doi:10.3760/cma.j.issn.1673-4114.2010.02.004]
[12]胡旻,刘雅洁,许小飞,等.99Tcm-MIBI动态血流灌注显像和双时相核素显像对甲状腺冷结节良恶性的诊断价值研究[J].国际放射医学核医学杂志,2010,34(3):174.
　HU Min,LIU Ya-jie,XU Xiao-fei,et al.Study on the diagnostic value of 99Tcm-MIBI dynamic blood flow perfusion imaging and double-phase radionuclide imaging in benign and malignant cold thyroid nodules[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(2):174.
[13]杨帆,袁卫红.放射性核素显像鉴别甲状腺“冷结节”良恶性的研究进展[J].国际放射医学核医学杂志,2009,33(1):33.[doi:10.3760/cma.j.issn.1673-4114.2009.01.033]
　YANG Fan,YUAN Wei-hong.Study progress of nuclide imaging in the differential diagnosis of nonfunctional cold thyroid nodules[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(2):33.[doi:10.3760/cma.j.issn.1673-4114.2009.01.033]
[14]李昊颖.18F-氟脱氧葡萄糖PET全身显像时甲状腺意外瘤的检出及价值[J].国际放射医学核医学杂志,2007,31(3):148.
　LI Hao-ying.The value of whole body 18F-fluorodeoxyglucose PET in detecting thyroid incidentaloma[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(2):148.

备注/Memo

备注/Memo:
收稿日期:2014-12-01。
通讯作者:赵德善,Email:deshanzh@163.com
更新日期/Last Update: 1900-01-01